Table 1.

Baseline patient characteristics

	At baseline			At tocilizumab discontinuation
	Add-on (n=49)	Switch (n=53)	P values	Add-on (n=49)	Switch (n=53)	P values
Age, years	57.5 (11.5)	54.4 (13.7)	0.15	–	–
Female, N (%)	44 (90)	47 (89)	0.97	–	–
Disease duration, years	3.6 (3.4)	3.5 (2.9)	0.09	–	–
RF positivity, N (%)	34 (71)†	40 (82)‡	0.24	–	–
TJC28	6.1 (4.2)	6.9 (5.5)	0.46	0.3 (0.6)	0.5 (1.0)	0.28
SJC28	5.4 (3.4)	7.0 (4.4)	0.04	0.3 (2.6)	0.2 (0.5)	0.62
TJC68	9.5 (7.3)	8.9 (8.1)	0.69	0.4 (0.7)	0.5 (1.4)	0.53
SJC66	6.3 (4.1)	10.1 (8.1)	0.004	0.4 (0.9)	0.3 (0.7)	0.31
CRP, mg/dL	1.0 (1.2)	1.2 (2.2)	0.56	0.09 (0.49)	0.02 (0.45)	0.06
ESR, mm/h	46 (23)	38 (27)	0.54	6 (5)	6 (4)	0.60
PGA, mm	48 (21)	47 (24)	0.98	12 (14)	9 (11)	0.24
EGA, mm	48 (21)	47 (18)	0.87	5 (5)	6 (12)	0.64
DAS28-ESR	4.9 (1.0)	5.0 (1.1)	0.66	1.4 (0.6)	1.4 (0.6)	0.78
HAQ-DI	0.84 (0.55)	0.89 (0.64)	0.74	0.32 (0.36)	0.31 (0.73)	0.98
MMP-3, mg/dL	190 (180)	159 (179)	0.74	55 (29)	55 (32)	0.73

Values are presented as mean (SD) unless otherwise stated.

*P<0.05.

†n=48.

‡n=49.

CRP, C reactive protein; DAS28, disease activity score for 28 joints; EGA, evaluator global assessment; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MMP, matrix metalloproteinase; PGA, patient global assessment; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count.